Transcatheter treatment tricuspid regurgitation by valve-in-ring implantation with a novel balloon-expandable Myval® THV

Hüseyin Ayhan¹, Bilge Duran Karaduman¹, Telat Keleş², Engin Bozkurt³

¹Department of Cardiology, Faculty of Medicine, Medicana International Ankara Hospital, Atılım University, Ankara, Turkey
²Department of Cardiology, Faculty of Medicine, Ankara City Hospital, Ankara Yıldırım Beyazıt University, Ankara, Turkey
³Department of Cardiology, Medicana International Ankara Hospital, Ankara, Turkey

Correspondence to:
Prof. Hüseyin Ayhan, MD, PhD,
Department of Cardiology,
Faculty of Medicine,
Medicana International Ankara Hospital,
Atılım University,
Çankaya, 068510 Ankara, Turkey,
phone: +90 505 865 62 94,
e-mail: huseyinayhan44@yahoo.com
Copyright by the Author(s), 2022
DOI: 10.33963/KP.a2022.0013
Received: October 18, 2021
Accepted: January 16, 2022
Early publication date: January 18, 2022

Transcatheter tricuspid valve-in-valve (TVIV) and valve-in-ring (TVIR) implantation procedures have emerged as important alternatives for high-risk patients [1].

A 59-year-old female patient, who first underwent closed mitral commissurotomy for mitral stenosis in 1989, was admitted to our department with complaints of dyspnea and edema in the legs and abdomen. The patient had a mitral valve replacement in 1991 and, in 2016, an aortic valve replacement and implantation of a 34-mm Edwards MC3 rigid partial ring (Edwards Lifesciences, LLC, Irvine, CA, US) were performed, together with tricuspid commissurotomy and patch augmentation. Transthoracic echocardiography (TTE) reported massive tricuspid regurgitation, increased tricuspid gradient (mean gradient 8 mm Hg), functional aortic and mitral prosthetic valves, and a preserved left ventricular ejection fraction (LVEF; 55%). Multislice computed tomography (MSCT) demonstrated the shape of the annuloplasty ring very well, and measurements of the ring area, circumference (933 mm), and diameter (30 mm) were performed in detail without thrombus and vegetation (Figure 1A).

After analyzing the literature evaluating Edwards MC3 34-mm Tricuspid annuloplasty partial ring and the echocardiography and MSCT findings, it was decided to implant the 32-mm Myval transcatheter heart valve (THV) system (Meril Life Sciences Pvt. Ltd., Vapi, Gujarat, India). As the right femoral vein was large, tortuous and edematous on examination, the procedure was performed under sedation in the left femoral vein with TTE. We crossed the valve with 6 Fr Multipurpose MPA1 via a 0.35-inch hydrophilic guidewire, and the Lunderquist Extra-Stiff Wire Guide (LES; Cook Inc., Bloomington, IN, US) was placed into the right ventricle. After an unsuccessful placing of a temporary pacing catheter via a jugular vein in the right ventricle, the system was prepared for rapid pacing over the stiff guidewire that would carry the valve system. Then the 32-mm Myval THV balloon-expandable valve was slowly implanted to avoid deforming the partial annuloplasty under the rapid pacing (180 bpm) in the precise position on fluoroscopy (Figure 1B, Supplementary material, Video S1). Incomplete rings lead to a higher risk of valve overexpansion, embolization, and paravalvular leaks, which can be avoided by a cautious and slow positioning of the THV. For the Myval positioning, detailed preparation was performed with multimodality imaging before the procedure, various positions were searched under the scope, and implantation was attempted by seeing the annuloplasty ring nearly at the same level. After Myval functions were observed to be good in hemodynamic, echocardiographic, and fluoroscopic controls, the procedure was terminated by applying an eight-shaped suture to the femoral vein (Figure 1C, Supplementary material, Video S2).

Valve dysfunction or degeneration after tricuspid valve replacement or repair with annuloplasty ring is frequent. It increases the
morbidity and mortality of the patients and may require redo surgery. Currently, to overcome this dilemma, case series concerning transcatheter TVIV or TVIR have emerged due to the risk of redo surgery. Transcatheter TVIR is a more challenging procedure than transcatheter TVIV, and successful and unsuccessful cases with Edwards Sapien XT, SAPIEN 3 (Edwards Lifesciences, Irvine, CA, US), and Melody (Medtronic, Minneapolis, MN, US) THV systems have been described [2–5].

To our knowledge, this first case report showed that the novel balloon-expandable Myval THV system is suitable for transcatheter TVIR.

**Supplementary material**

Supplementary material is available at https://journals.viamedica.pl/kardiologia_polska.

**Article information**

**Acknowledgment:** We would like to acknowledge Hakan Ulubay and Aşkın Yeşilyurt for their support in performing cardiac computed tomography.

**Conflict of interest:** None declared.

**Open access:** This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially. For commercial use, please contact the journal office at kardiologiapolska@ptkardio.pl.

**REFERENCES**